You are here
A/Professor Vera Ignjatovic
Associate Professor Ignjatovic is the Co-Group Leader of Haematology Research at Murdoch Childrens Research Institute. She established the Haematology Research Laboratory in 2001 and built a highly productive and internationally competitive team through supervision, support and mentoring of higher degree students and research assistants, roles critical to the success of her team.
A/Prof Ignjatovic has made major contributions in defining age-specific development of the haemostatic system (Developmental Haemostasis) and the use of anticoagulants in children. Her research offers a unique opportunity to study differences in the haemostatic system of children compared to adults that contribute to low incidence of spontaneous thrombosis in children and increased thrombosis in ageing populations. This supports development of strategies for prevention and evidence-based treatment for thrombosis based on sound scientific knowledge.
A/Prof Ignjatovic established the first normative dataset for haemostatic proteins in Australia, results that were translated to international clinical guidelines.
She pioneered the world-first study of the effects, pharmacokinetics and strategies for monitoring anticoagulants in children and established the concept of 'ageing of the plasma proteome'. A/Prof Ignjatovic's research has been translated into improved anticoagulation therapy for thousands of children.
She is a co-founder of the Human Proteome Organisation (HUPO) PediOme initiative for proteomics in paediatrics (2013) and is a member of the International Society on Thrombosis and Haemostasis (ISTH) Ethics Committee. She will co-chair a session at the HUPO 2014 congress and will be an editor of the paediatric edition of Proteomics Clinical Applications.
- Principal Fellow, Department of Paediatrics, The University of Melbourne
- Clinical Scientist Funding Award – Human Proteome Organisation, 2014
- Scientific Visits to Europe Award – Australian Academy of Science, 2010
- Young Investigator Award – International Society on Thrombosis and Haemostasis, 2009
- Clinical Fellowship Award – Sanofi Aventis/International Society on Thrombosis and Haemostasis, 2007
- Young Investigator Award - International Society on Thrombosis and Haemostasis, 2007
- Travelling Fellowship – Royal Children's Hospital, 2003
- Travel Fellowship - Haematology Society of Australia and New Zealand, 2003
- Travelling Fellowship - Paediatric Research Society of Australia and New Zealand, 2003
Associate Professor Ignjatovic's research focuses on the concept known as Developmental Haemostasis, which describes that the blood clotting (haemostatic) system develops (matures) with age. It is specifically the differences in the haemostatic system between newborns and children as compared to adults that are thought to provide an added level of protection to younger populations from bleeding and clotting events.
Her research focuses on investigating the age-specific structure-function relationships of haemostatic proteins and how these contribute to interaction of haemostatic proteins with clinically relevant medicines such as heparin. The major aims being to improve understanding and treatment of blood clotting disorders in children; to better understand, use and monitor anticoagulation therapy in children, as well as to understand why the younger infants and children are less prone to spontaneous bleeding and clotting events, which will in turn advance our ability to protect adults from such events and to develop effective treatment strategies.
In 2008 A/Prof Ignjatovic added proteomics to her research portfolio, with particular emphasis on investigations of age-specific differences in the plasma and platelet proteomes and how these differences contribute to the process of ageing. She has for the first time described the concept of "Ageing of the plasma proteome" and pioneered studies focusing on changes in plasma proteome in the setting of cardiac surgery.
She aims to continue to place Australia at the forefront of paediatric thrombosis and haemostasis, translating research outcomes into practice and improving the health of individuals worldwide.
- Personalised Anticoagulation
- Blood clot formation and structure
- Platelet phenotype and function
- Structural differences in Antithrombin
- Bleeding and Thrombotic outcomes post-FONTAN surgery
Karlaftis V, Sritharan G, Attard C, Monagle P, Ignjatovic V. Beta (ß)-Antithrombin Activity in Children and Adults: Implications for heparin therapy in infants and children. Journal of Thrombosis and Haemostasis. 2014;12(7):1141-1144.
Monagle P, Attard C, Karlaftis V, Ignjatovic V. Personalised anticoagulation approach to improve the prevention and treatment of thrombosis. Thrombosis Research. 2014;134(1): 204-206.
Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental haemostasis: age-specific differences in the quantity of haemostatic proteins. Journal of Thrombosis and Haemostasis . 2013;11(10):1850-4.
Yip C, Ignjatovic V, Attard C, Monagle P, Linden M. First report of elevated monocyte-platelet aggregates in healthy children. PLoS ONE . 2013;8(6):e67416.
Hepponstall M, Ignjatovic V, Binos S, Monagle P, Jones B, Cheung M.H.H, d'Udekem Y, Konstantinov I.E. Remote Ischemic Preconditioning Modifies Plasma Proteome in Humans. PLoS ONE. 2012;7(11): e48284.
Attard C, Monagle P, Kubitza D, Ignjatovic V. The in vitro anticoagulant effect of Rivaroxaban in children. Thrombosis Research. 2012;130(5):804-7.
Ignjatovic V, Kenet G, Monagle P. Developmental Haemostasis: Recommendations for laboratories reporting paediatric samples. Journal of Thrombosis and Haemostasis. 2012;10(2)298-300.
Ignjatovic V, Lai C, Summerhayes R, Mathesius U, Tawfilis S, Perugini MA, Monagle P. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS ONE. 2011;6(2): e17213.
Ignjatovic V, Ilhan A, Monagle P. Evidence for age-related differences in human fibrinogen. Blood Coagulation and Fibrinolysis. 2011;22(2): 110–7.
Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. Journal of Thrombosis and Haemostasis. 2010;8(6):1290-1294.